Cantor Fitzgerald raised the firm’s price target on BioMarin to $110 from $100 and keeps an Overweight rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, raised its target for BioMarin to account for upcoming cost cuts. The “usual seasonal headwinds that typically make this one of the weaker quarters for the industry,” the analyst added in the preview note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- Biomarin Pharmaceutical Inc. (BMRN) Q1 Earnings Cheat Sheet
- BioMarin participates in a conference call with JPMorgan.
- BioMarin presents new data for Voxzogo in achondroplasia and achondroplasia
- Fly Insider : Echostar, Dell among week’s notable insider trades
- BioMarin exec Fuchs sells 35,341 common shares
